// App-Quantinova.ai

: Immune Microenvironment Analysis of Bone Marrow By Mass Cytometry and RNA Sequencing in Multiple Myeloma Patients Treated with Daratumumab and Durvalumab

Researchers

Presenter

  • Frances Seymour

Principal Investigators

  • Mary H Young

  • Mark Tometsko

  • Jamie Cavenagh

  • Ethan G. Thompson

  • Elizabeth Whalen

  • Sam A Danziger

  • Alison Fitch

  • Brian A. Fox

  • Andrew Dervan

  • Teri Foy

  • Katie Newhall

  • John G. Gribben

Medical Centers

  • Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Immuno-Oncology Thematic Center of Excellence, Celgene Corporation, Seattle, WA

  • Celgene Corporation, Seattle, WA

  • Department of Histopathology, St. Bartholomews Hospital, London, United Kingdom

  • Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • daratumumab Intravenous

  • Durvalumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02807454

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved